PT-141: a beginner's guide to the desire peptide

Key takeaways

• PT-141 is bremelanotide, a lab-made peptide given as a small injection under the skin. Instead of boosting blood flow like the erectile-dysfunction pills, it acts on the brain's melanocortin system, though the FDA label says the exact way it lifts desire is not fully understood .
• It is FDA-approved, but the approval is narrow. As Vyleesi (approved in 2019) it is cleared only for premenopausal women with low sexual desire that causes real distress, a condition called HSDD. It is not approved for men, postmenopausal women, or performance .
• The approval rests on two modest trials. The RECONNECT program randomized 1,267 premenopausal women, and desire rose by a small but statistically real amount, about 0.35 points on the desire scale. A later review noted some of that response may be placebo .
• Nausea is the headline side effect: about 40 percent of women in the trials, worst after the first dose. Flushing hit about 20 percent versus under 1 percent on placebo .
• Each dose nudges blood pressure up for a few hours, so it is contraindicated in uncontrolled high blood pressure or known heart disease. That is the hardest line here .
• The FDA-approved product is a fixed 1.75 mg subcutaneous autoinjector . The freeze-dried vials and nasal sprays labeled PT-141 online are not that product, so their purity, identity, and dose are unverified.

The short version: a real approval on a narrow, modest base

PT-141 is short for a compound called bremelanotide. It is a small lab-made peptide, and unlike Viagra or Cialis, which open up blood flow, it works on a signaling system in the brain called the melanocortin system . The honest caveat, right up front: the label itself says the exact way it improves desire is unknown .

What it is: a brain-signal peptide, not a blood-flow pill

Bremelanotide switches on melanocortin receptors, a family of signals your body uses for everything from skin pigment to arousal . The receptor tied to desire (MC4R) sits on nerve cells throughout the brain, which is why the effect is described as central, a change in drive, rather than a plumbing fix .

In its approved form it is a single-use autoinjector you press against the skin of the belly or thigh, taken as needed before sex rather than on a daily schedule . That is a different rhythm from most peptides, which run on a fixed routine.

What people use it for: desire, and when the ED pills fall short

The approved use is narrow: premenopausal women whose sexual desire has dropped enough to cause real distress, which is what HSDD means . That one group is where the actual evidence lives.

Most use is off-label. Men reach for it when the usual erectile-dysfunction pills have stopped doing enough, since PT-141 works on desire through the brain instead of only on blood flow. Postmenopausal women use it outside the label, and couples use it to break a slump. The reported effect is more of a mental drive than a purely physical response.

None of those off-label uses have approval-grade evidence. They are user reports and habit, not trial results, and the blood-pressure caution and the heart-disease contraindication apply no matter who is taking it .

What the science shows: FDA-approved, but on two modest-effect trials

This is the part worth slowing down on, because FDA-approved sounds bigger than the data is. The approval rests on the RECONNECT program: two identically designed, company-run trials that together randomized 1,267 premenopausal women with HSDD to bremelanotide or a placebo . Each was a phase 3, double-blind, placebo-controlled study of the fixed 1.75 mg subcutaneous dose .

Both trials hit their main goals, but the effects were small. Desire rose by about 0.35 points on the standard desire scale versus placebo, with a matching drop in the distress women felt about low desire . Real and statistically solid, but modest. A later peer-reviewed review even flagged that some of the high response may come down to the placebo effect, a point the trial authors themselves raised .

Two limits matter more than the effect size. First, every participant was a premenopausal woman with HSDD, so the trials say nothing solid about men, postmenopausal women, or erectile dysfunction . Second, the approved product is a subcutaneous injection . A nasal spray or a research vial labeled PT-141 is not the studied product, and the label's dose and timing do not transfer to it.

The catch: a real blood-pressure and nausea profile, and an online-product problem

• Blood pressure and the heart come first. Each dose raises blood pressure a little (about 6 mmHg systolic and 3 mmHg diastolic) with a small dip in heart rate, peaking 2 to 4 hours later and usually back to baseline within about 12 hours . Because of that, it is contraindicated in uncontrolled hypertension or known cardiovascular disease, and the sensible move is to have your blood pressure well controlled before you ever start .
• Nausea is the most common reaction by far: about 40 percent of women, worst after the first dose (21 percent), which is why some people pre-empt it. In the trials, 13 percent needed an anti-nausea med and 8 percent quit over it .
• Skin darkening can stick. Focal hyperpigmentation of the face, gums, or breasts showed up in about 1 percent at up to eight doses a month, and much more with frequent use (38 percent in a study dosing daily for eight days). People with darker skin were more likely to get it, and the label says it did not always resolve after stopping .
• Do not mix it with oral naltrexone. Bremelanotide can significantly lower how much naltrexone gets into your system, which can undercut naltrexone's job in treating alcohol or opioid dependence .
• Skip it if you are or might be pregnant. The label says to stop if pregnancy is suspected and to use effective contraception, and there is no human data on breastfeeding .
• Flushing is common (about 20 percent versus under 1 percent on placebo), and it is usually a nuisance rather than a danger . Stop and get prompt care for any sign of a serious allergic reaction, or for chest symptoms or a blood-pressure reaction that worries you.
• What is actually in the vial is unverified. The freeze-dried and nasal PT-141 sold online is not the FDA-reviewed autoinjector, so purity, identity, and the real dose are not guaranteed .

How people take it, and where the real numbers live

If you are going to use it, the goal is to stay as close to the studied version as the unknowns allow. The approved product is a fixed 1.75 mg subcutaneous autoinjector to the abdomen or thigh, taken as needed at least 45 minutes before sex, with no more than one dose in 24 hours and no more than eight a month . Those last two limits are the ones people ignore and should not, since skin darkening climbs sharply with frequent dosing .

One more thing worth building in from the start: because a research vial is not the pharmacy product, a third-party certificate of analysis is the one quality lever you actually control. And if you have any blood-pressure or heart history, that is the conversation to have before the first dose, not after.

Where to go deeper

This guide is the on-ramp. For the full trial-by-trial picture, the PT-141 evidence map walks the RECONNECT data and the dose-finding work in detail, and the melanocortin system explained covers how MC4R and its cousins actually drive the effect. If you are weighing where PT-141 sits among the peptides people ask about most, the most in-demand peptides of 2026 puts it in context, and spotting high-quality peptides in 2026 is the guide to the purity problem the risk section keeps pointing at. The PT-141 library entry is the quick reference for dosing ranges, storage, and sources.

How we sourced this, and the fine print

Every claim here is pinned to a published source: the FDA label on DailyMed, the pivotal RECONNECT trials, the trial registry record, and a peer-reviewed review. Where the human evidence stops at premenopausal women, this guide says so instead of stretching it to everyone who uses the peptide.

For research and educational purposes only. Not medical advice.

pepSmart has not commissioned independent clinical review of this article.

More on how we write and source these guides: Editorial process and contributor disclosure and Sourcing posture.

Spot an error? Email corrections via /about.

Sources: 4 entries, all primary or authoritative (the FDA label via DailyMed, the pivotal PubMed trial, a PubMed Central review, and the ClinicalTrials.gov trial registry), last reviewed 2026-07-13.

Related tools

• Peptide reconstitution calculator - Convert vial mass and BAC water volume into mcg/ml.
• BAC water calculator - Solve BAC water volume for a target concentration.
• Multi-dose vial calculator - Estimate doses per vial and a projected vial-empty date.
• Reconstituted-vial storage window calculator - Estimate a generic usable-window date and days remaining.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.